Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(14%)
Results Posted
100%(4 trials)

Phase Distribution

Ph phase_4
1
14%
Ph phase_3
2
29%
Ph phase_2
3
43%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Active, not recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (50.0%)
Phase 32 (33.3%)
Phase 41 (16.7%)

Trials by Status

completed457%
active_not_recruiting114%
unknown114%
withdrawn114%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_3

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

NCT05280548
withdrawnphase_4

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

NCT04143958
completedphase_2

Replagal Enzyme Replacement Therapy for Children With Fabry Disease

NCT00084084
completedphase_2

This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

NCT01304277
completedphase_3

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

NCT01298141
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05280548Phase 3

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Active Not Recruiting
NCT04143958Phase 4

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

Withdrawn
NCT00084084Phase 2

Replagal Enzyme Replacement Therapy for Children With Fabry Disease

Completed
NCT01304277Phase 2

This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

Completed
NCT01298141Phase 3

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

Completed
NCT01031173

Treatment Protocol of Replagal for Patients With Fabry Disease

Unknown
NCT01196871Phase 2

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7